REGULATORY T CELL (TREG) EXTRACELLULAR VESICLE COMPOSITIONS AND METHODS

The present disclosure provides anti-inflammatory extracellular vesicles (EVs) derived from ex vivo-expanded human suppressive immune cells, e.g., regulatory T cells (Tregs). Such EVs are useful in the treatment of diseases such as amyotrophic lateral sclerosis (AES), Alzheimer's disease, and o...

Full description

Saved in:
Bibliographic Details
Main Authors THONHOFF, JASON ROBERT, THOME, AARON DREW, APPEL, STANLEY HERSH
Format Patent
LanguageEnglish
French
Published 01.09.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides anti-inflammatory extracellular vesicles (EVs) derived from ex vivo-expanded human suppressive immune cells, e.g., regulatory T cells (Tregs). Such EVs are useful in the treatment of diseases such as amyotrophic lateral sclerosis (AES), Alzheimer's disease, and other neurological diseases, as well as inflammatory and autoimmune diseases or dysfunctions. La présente divulgation concerne des vésicules extracellulaires anti-inflammatoires (EV) dérivées de cellules immunitaires suppressives humaines étendues ex vivo, par exemple, des lymphocytes T régulateurs (treg). De telles EV sont utiles dans le traitement de maladies telles que la slérose latérale amyotrophique (AES), la maladie d'Alzheimer et d'autres maladies neurologiques, ainsi que des maladies ou des dysfonctionnements inflammatoires et auto-immuns.
Bibliography:Application Number: CA20223210656